Preliminary study of proteomic shift from normal to premalignant laryngeal lesions and to laryngeal squamous cell carcinoma
Preliminary study of proteomic shift from normal to premalignant laryngeal lesions and to laryngeal squamous cell carcinoma
复制标题
正常喉部病变至癌前病变及喉鳞状细胞癌蛋白质组转变的初步研究
DOI：
10.1080/00016480802412797
复制
发表时间：
2009-01-01
影响因子：
1.4
通讯作者：
Liu, Yinkun
中科院分区：
文献类型：
--
作者：
Cheng, Lei;Zhou, Liang;Liu, Yinkun
结论：在喉鳞状细胞癌（LSCC）和健康对照组的癌前病变（PMLL）的比较中发现，恶性转移甚至在癌前阶段就开始开始。蛋白质在正常、PMLL和癌细胞中的差异表达可能为从正常到PMLL和恶性疾病的变化提供预测。目的：研究正常人、PMLL及喉鳞状细胞癌（LSCC）患者血清蛋白质组变化。材料与方法：在知情同意的情况下，从患有LSCC（n=89在I-II期）或PMLL（n=57）或正常对照（n=65）的患者中获得总共211个血清样本。采用表面增强激光解吸/电离质谱（SELDI-TOF MS）对血清蛋白质进行弱阳离子交换（WCX 2）分析，然后采用Biomarker Wizard软件进行分析。结果：PMLL患者血清与正常人及喉鳞癌患者血清的峰值强度比较。喉鳞癌与癌前病变之间仅一个峰（4532 Da，p=0.032）的平均强度存在显著差异，而癌前病变与正常对照之间有13个峰存在显著差异。选择18种生物标志物来区分I-II期LSCC患者和健康对照。
Conclusions: The malignant shift was discovered to begin even in the premalignant stage in the comparison of premalignant laryngeal lesions (PMLLs) with laryngeal squamous cell carcinoma (LSCC) and healthy controls. The differential expression of proteins among normal, PMLL, and cancer cells might provide the prediction for the changes from normal to PMLL and to malignant disease. Objectives: To study the serum proteomic shift from normal control to PMLL and progression to LSCC. Materials and methods: A total of 211 serum samples from patients with LSCC (n=89 at stage I–II) or PMLL (n=57), or normal controls (n=65) were obtained with informed consent. Serum protein profiles on weak cationic exchange (WCX2) were performed by surface-enhanced laser desorption/ionization mass spectrometry (SELDI-TOF MS) and then analyzed by Biomarker Wizard software. Results: Peak intensities of serum from PMLLs were compared to normal controls and serum from patients with LSCC. Mean intensity differed significantly only for one peak (4532 Da, p=0.032) between LSCC and precancerous diseases, while 13 peaks differed significantly between precancerous diseases and normal controls. Eighteen biomarkers were selected to separate stage I– II LSCC patients and healthy controls.